Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.340
+0.020 (1.52%)
At close: Jun 2, 2025, 4:00 PM
1.350
+0.010 (0.75%)
After-hours: Jun 2, 2025, 4:00 PM EDT

Chemomab Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2018 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Selling, General & Admin
3.513.417.0811.566.031.29
Upgrade
Research & Development
10.6711.3318.3816.986.334.68
Upgrade
Operating Expenses
14.1814.7425.4628.5312.375.97
Upgrade
Operating Income
-14.18-14.74-25.46-28.53-12.37-5.97
Upgrade
Interest Expense
-----0.11-
Upgrade
Interest & Investment Income
0.770.791.220.35-0.04
Upgrade
Currency Exchange Gain (Loss)
0.010.010.01---0.02
Upgrade
Pretax Income
-13.4-13.95-24.22-28.18-12.48-5.95
Upgrade
Income Tax Expense
----0.53--
Upgrade
Net Income
-13.4-13.95-24.22-27.65-12.48-5.95
Upgrade
Net Income to Common
-13.4-13.95-24.22-27.65-12.48-5.95
Upgrade
Shares Outstanding (Basic)
20181211107
Upgrade
Shares Outstanding (Diluted)
20181211107
Upgrade
Shares Change (YoY)
60.31%52.79%3.26%9.70%51.71%-
Upgrade
EPS (Basic)
-0.67-0.78-2.06-2.43-1.20-0.87
Upgrade
EPS (Diluted)
-0.67-0.78-2.06-2.43-1.20-0.87
Upgrade
Free Cash Flow
--15.39-23.61-20.44-12.61-5.28
Upgrade
Free Cash Flow Per Share
--0.86-2.01-1.80-1.22-0.77
Upgrade
EBITDA
-14.13-14.69-25.39-28.48-12.33-5.95
Upgrade
D&A For EBITDA
0.050.050.070.060.030.02
Upgrade
EBIT
-14.18-14.74-25.46-28.53-12.37-5.97
Upgrade
Updated Apr 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q